Parte del contenido de esta aplicación no está disponible en este momento.
Si esta situación persiste, contáctenos aComentarios y contacto
1. (WO2019043192) TLR-9 AGONISTS FOR MODULATION OF TUMOR MICROENVIRONMENT



Descargo de responsabilidad La versión en formato de imagen PDF que figura en PATENTSCOPE es la versión oficial. Esta versión html en línea tiene por objeto asistir a los usuarios. Pese a que se ha tenido sumo cuidado al compilar los datos a fin de garantizar una representación exacta y rigurosa de los contenidos que figuran en el documento impreso o las imágenes impresas, cabe la posibilidad de que haya errores u omisiones por causa de los procesos de transmisión y conversión de datos, así como de las limitaciones inherentes de la traducción automática (opcional). Los enlaces de hipertexto seguidos del símbolo son enlaces a recursos externos que no están administrados por la OMPI. La OMPI declina toda responsabilidad respecto de los puntos anteriores.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/EP2018/073534 59 814 K
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
31 August 2018 31 August 2017
Applicant
MOLOGEN AG
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     A61P 35/00 (2006.01)i; A61K 31/7088 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     A61K; A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, BIOSIS, INSPEC, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WO 2017042336 A1 (MOLOGEN AG [DE]) 16 March 2017 (2017-03-16)
1-18
Y
the whole document
1-18
claims; examples; sequences
(2)
X
WO 2012085291 A1 (MOLOGEN AG [DE]; SCHROFF MATTHIAS [DE]; KLEUSS CHRISTIANE [DE]; KAPP K) 28 June 2012 (2012-06-28)
1-18
Y
the whole document
1-18
claims; examples; sequences
(3)
X
MANUEL SCHMIDT ET AL, "Combination of TLR9 agonist lefitolimod/MGN1703 with checkpoint inhibitors for cancer immunotherapy.", JOURNAL OF CLINICAL ONCOLOGY,Vol. 35, No. 4_suppl, 01 February 2017 (2017-02-01), page 634-634,
XP055521083
1-18
Y
abstract
1-18
(4)
X
MANUEL SCHMIDT ET AL, "TLR9 agonist lefitolimod to improve antitumor effect of checkpoint inhibitors in vivo.", JOURNAL OF CLINICAL ONCOLOGY,Vol. 35, No. 15_suppl, 20 May 2017 (2017-05-20), page e14625-e14625,
XP055521123
1-18
Y
abstract
1-18
(5)
X
BURGHARDT WITTIG ET AL, "MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY,Vol. 94, No. 1, 01 April 2015 (2015-04-01), page 31-44,
XP055183411
1-18
Y
the whole document
1-18
paragraphs [06.3], [0007]; figures; tables
(6)
X
HANS-JOACHIM SCHMOLL ET AL, "Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,10 May 2014 (2014-05-10),
XP055131369
1-18
Y
the whole document
1-18
abstract; figures
(7)
Y
MANUEL SCHMIDT ET AL, "Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703", NUCLEIC ACID THERAPEUTICS,Vol. 25, No. 3, 01 June 2015 (2015-06-01), page 130-140,
XP055521297
1-18
the whole document
(8)
Y
WEIHRAUCH ET AL, "Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours", EUROPEAN JOURNAL OF CANCER,,02 December 2014 (2014-12-02), page 146-156,
XP002774732
1-18
the whole document
(9)
Y
KERSTIN KAPP ET AL, "Genuine Immunomodulation With dSLIM", MOLECULAR THERAPY-NUCLEIC ACIDS,Vol. 3, No. 6, 24 June 2014 (2014-06-24), page e170,
XP055183412
1-18
the whole document
(10)
A
LINE VIBHOLM ET AL, "Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection", CLINICAL INFECTIOUS DISEASES,Vol. 64, No. 12, 15 June 2017 (2017-06-15), page 1686-1695,
XP055521325
1-18
the whole document
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2017042336 A1
16 March 2017
AU 2016319214 A1
BR 112018004246 A2
CA 2997319 A1
CN 108138179 A
EP 3347468 A1
JP 2018530530 A
KR 20180050309 A
US 2018251767 A1
WO 2017042336 A1
15 March 2018
25 September 2018
16 March 2017
08 June 2018
18 July 2018
18 October 2018
14 May 2018
06 September 2018
16 March 2017
WO 2012085291 A1
28 June 2012
AU 2011347095 A1
BR 112013015816 A2
CA 2822377 A1
CN 103370417 A
CN 107299101 A
CN 107384930 A
DK 2655623 T3
EP 2655623 A1
ES 2618783 T3
IL 227105 A
JP 6027542 B2
JP 2014504158 A
KR 20130126680 A
KR 20160113332 A
MX 343918 B
PL 2655623 T3
RU 2013132151 A
SG 191328 A1
US 2014010830 A1
WO 2012085291 A1
ZA 201304999 B
25 July 2013
29 May 2018
28 June 2012
23 October 2013
27 October 2017
24 November 2017
03 April 2017
30 October 2013
22 June 2017
28 September 2017
16 November 2016
20 February 2014
20 November 2013
28 September 2016
29 November 2016
30 June 2017
27 January 2015
31 July 2013
09 January 2014
28 June 2012
26 February 2014
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
07 November 2018
Date of mailing of the international search report:
26 November 2018
Authorized officer:
Orlando, Michele
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E